Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

The prognostic role of tumor infiltrating lymphocytes (TIL) has been confirmed in triple negative early breast cancer and there may be a prognostic impact in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors, a new study published online early in the journal Annals of Oncology has shown.

For the study, researchers analyzed data from two multicenter, randomized trials that included 816 patients with breast cancer. Only patients who received adjuvant anthracyclines or no chemotherapy were included in the analysis.

Results showed that Intratumoral TIL and Stromal TIL were strong prognostic factors for overall survival (HR = 0.85; 95% CI: 0.77-0.95; P = 0.003; HR = 0.89; 95% CI: 0.81-0.96; P = 0.005, respectively). Researchers found that the prognostic effect of continuous TIL was limited to patients with triple negative and HER2-positive disease.

The study also showed that TIL should not be used as a parameter to identify patients to receive treatment with anthracyclines.

Analysis from phase II ENDEAVOR trial showed Kyprolis and dexamethasone superior to Velcade and dexa
The prognostic role of tumor infiltrating lymphocytes has been confirmed in triple negative early breast cancer.
Tumor infiltrating lymphocytes (TIL) are emerging as strong prognostic factor for early breast cancer patients, especially in the triple negative subtype.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs